Skip to content
DataLookout
Menu

NCT07939919

A Study of AK158D1 in Advanced Solid Tumors

StatusNot Yet Recruiting
PhasePhase 1
SponsorAkeso
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Dose Limiting Toxicities (DLTs)
Timeframe: At the end of Cycle 1 (each cycle is 21 days)
Adverse Events (AEs)
Timeframe: Up to approximately 2 years

Secondary (8)

Pharmacokinetics (PK) Characteristics
Anti-Drug Antibodies (ADA)
Objective Response Rate (ORR)
Disease Control Rate (DCR)
Duration of Response (DoR)
Show 3 moreShow less
Time to Response (TTR)
Progression Free Survival (PFS)
Overall Survival (OS)

Arms and interventions

AK158D1Experimental

Drugs: AK158D1

Sites

2 sites in 1 country